US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Urovant Sciences Ltd.

16.24

0.0000

Volume:- -

Turnover:- -

Market Cap:531.75M

PE:-3.09

High:16.24

Open:16.24

Low:16.24

Close:16.24

52wk High:16.26

52wk Low:7.15

Shares:32.74M

Float Shares:6.61M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.2539

EPS(LYR):-4.8245

ROE:218.18%

ROA:-75.13%

PB:-3.65

PE(LYR):-3.37

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Urovant Sciences Ltd.

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.urovant.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/UROV/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"UROV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UROV\",,,,,undefined,":{"symbol":"UROV","market":"US","secType":"STK","nameCN":"Urovant Sciences Ltd.","latestPrice":16.24,"timestamp":1616788800000,"preClose":16.24,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":6612018,"shares":32743396,"eps":-5.253893,"marketStatus":"Halted","change":0,"latestTime":"03-26 16:00:00 EDT","open":16.24,"high":16.24,"low":16.24,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.253893,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1538020800000,"exchange":"NASDAQ","adjPreClose":16.24,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UROV\",,,,,undefined,":{"symbol":"UROV","floatShares":6612018,"roa":"-75.13%","roe":"218.18%","lyrEps":-4.824497,"shares":32743396,"dividePrice":0,"high":16.24,"amplitude":0,"preClose":16.24,"low":16.24,"week52Low":7.15,"pbRate":"-3.65","week52High":16.26,"institutionHeld":0,"latestPrice":16.24,"eps":-5.253893,"divideRate":0,"volume":0,"delay":0,"ttmEps":-5.253893,"open":16.24,"prevYearClose":16.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UROV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-03-30","symbol":"UROV","reason":null,"defaultRemindTime":1617111000000,"announcedDate":"2021-03-26","type":"delisting","dateTimestamp":1617076800000},{"market":"US","date":"2021-02-12","symbol":"UROV","fiscalQuarterEnding":"2020/12","expectedEps":-1.59,"name":null,"time":"","type":"earning","dateTimestamp":1613106000000,"reportTimeType":"","actualEps":-1.46},{"date":"2020-11-02","symbol":"UROV","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2020/09","expectedEps":-1.5,"defaultRemindTime":1604350800000,"name":null,"time":"Post Market","dateTimestamp":1604293200000,"actualEps":null},{"date":"2020-08-13","symbol":"UROV","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2020/06","expectedEps":-1.36,"defaultRemindTime":1597348800000,"name":null,"time":"Post Market","dateTimestamp":1597291200000,"actualEps":null},{"date":"2020-06-18","symbol":"UROV","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2020/03","expectedEps":-1.25,"defaultRemindTime":1592510400000,"name":null,"time":"Post Market","dateTimestamp":1592452800000,"actualEps":-0.96}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UROV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UROV\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UROV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UROV","date":"2021-03-26","current":-3.091041,"percent":0.6094,"low":-15.852864,"twenty":-8.940566,"median":-4.197764,"eighty":-2.174234,"high":-1.487225,"avg":-5.440772,"sd":3.662094,"marketCap":531425317},"quantilePoints":[{"date":"2021-02-25","current":-3.236197,"twenty":-9.019268,"median":-4.347757,"eighty":-2.159281,"marketCap":529788147},{"date":"2021-03-05","current":-3.236197,"twenty":-8.99903,"median":-4.326776,"eighty":-2.165434,"marketCap":529788147},{"date":"2021-03-12","current":-3.242198,"twenty":-8.987787,"median":-4.315304,"eighty":-2.168001,"marketCap":530770449},{"date":"2021-03-19","current":-3.246198,"twenty":-8.969798,"median":-4.282506,"eighty":-2.168982,"marketCap":531425317},{"date":"2021-03-26","current":-3.246198,"twenty":-8.940566,"median":-4.197764,"eighty":-2.174234,"marketCap":531425317}],"updateTime":1771805689715},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.urovant.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.","exchange":"NASDAQ","name":"Urovant Sciences Ltd.","nameEN":"Urovant Sciences Ltd."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"UROV\",market:\"US\",,,undefined,":null}}